3 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 16,949 as of Wednesday, Aug. 20, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,589 declining with 185 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Idexx Laboratories ( IDXX), down 3.2%, Sanofi ( SNY), down 1.0% and Alexion Pharmaceuticals ( ALXN), down 0.6%. Top gainers within the industry include Jazz Pharmaceuticals ( JAZZ), up 2.7%, Dr Reddy Laboratories ( RDY), up 2.5%, Biomarin Pharmaceutical ( BMRN), up 2.5%, Illumina ( ILMN), up 2.2% and Novo Nordisk A/S ( NVO), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Bristol-Myers Squibb Company is down $0.27 (-0.5%) to $50.03 on light volume. Thus far, 1.4 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.9 million shares. The stock has ranged in price between $49.88-$50.29 after having opened the day at $50.07 as compared to the previous trading day's close of $50.30.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $82.9 billion and is part of the health care sector. Shares are down 5.4% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, notable return on equity, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $2.58 (-0.8%) to $343.26 on light volume. Thus far, 343,687 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $343.10-$345.46 after having opened the day at $343.68 as compared to the previous trading day's close of $345.84.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $81.4 billion and is part of the health care sector. Shares are up 23.3% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is down $0.34 (-0.6%) to $54.95 on light volume. Thus far, 2.9 million shares of AbbVie exchanged hands as compared to its average daily volume of 10.2 million shares. The stock has ranged in price between $54.69-$55.10 after having opened the day at $54.83 as compared to the previous trading day's close of $55.29.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $86.4 billion and is part of the health care sector. Shares are up 4.7% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists